Data Sheet 4: Sustained Response to TMEp-CI-M Platform in Refractory SCLC

A single-case report details a patient with PD-L1-negative extensive-stage small-cell lung cancer and brainstem metastasis treated with the TMEp-CI-M platform. The patient achieved no evidence of disease for over 20 months following a regimen of stereotactic body radiotherapy, low-dose etoposide, anlotinib, cadonilimab, and probiotics. The report was authored by Yating Wu and uploaded to figshare in June 2026.

Use Cases

• Analyze longitudinal treatment response based on ProGRP biomarker levels mentioned in the description
• Study adverse event profiles for combined radiotherapy, chemotherapy, and immunotherapy regimens
• Review a detailed clinical case for hypothesis generation in immuno-oncology research

Strengths

• Includes specific biomarker data, with ProGRP levels dropping from 1803 pg/mL to 23.71 pg/mL
• Reports a durable clinical outcome of over 20 months with no evidence of disease
• Provides a detailed description of a multi-phase therapeutic platform (TMEp-CI-M)

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data is limited to a single case report, which restricts generalizability

Provenance

Source

figshare

Collection Method

Clinical case report documentation.

Freshness

Last updated 2026-06-01 05:18:39; freshness should be verified